Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche/Genentech
Honoraria - Amgen; PharmaMar; Roche/Genentech
Stefan Sleijfer
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Saskia Litière
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; PharmaMar; Roche/Genentech
Research Funding - GlaxoSmithKline; Novartis; PharmaMar; Roche
Axel Le Cesne
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Zsuzsanna Papai
No relevant relationships to disclose
Ian Robert Judson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Patrick Schoffski
No relevant relationships to disclose
Sant P. Chawla
No relevant relationships to disclose
Thierry Gil
No relevant relationships to disclose
Sophie Piperno-Neumann
No relevant relationships to disclose
Sandrine Marreaud
No relevant relationships to disclose
Rachel Hodge
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Winette T.A. Van Der Graaf
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline